Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

GPR40: a therapeutic target for mediating insulin secretion (review).

Feng XT, Leng J, Xie Z, Li SL, Zhao W, Tang QL.

Int J Mol Med. 2012 Dec;30(6):1261-6. doi: 10.3892/ijmm.2012.1142. Epub 2012 Sep 26. Review.

PMID:
23023155
[PubMed - indexed for MEDLINE]
2.

[New pharmacological treatment methods of type 2 diabetes].

Madsbad S, Hermansen K.

Ugeskr Laeger. 2012 Sep 10;174(37):2143-6. Danish.

PMID:
22971293
[PubMed - indexed for MEDLINE]
3.

A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.

Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, Vakilynejad M.

Clin Pharmacol Ther. 2012 Jul;92(1):29-39. doi: 10.1038/clpt.2012.43. Epub 2012 Jun 6.

PMID:
22669289
[PubMed - indexed for MEDLINE]
4.

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.

Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, Ito R, Suzuki M, Takeuchi K, Suzuki N, Miyazaki J, Santou T, Odani T, Kanzaki N, Funami M, Morohashi A, Nonaka M, Matsunaga S, Yasuma T, Momose Y.

J Med Chem. 2012 Apr 26;55(8):3960-74. doi: 10.1021/jm300170m. Epub 2012 Apr 18.

PMID:
22490067
[PubMed - indexed for MEDLINE]
5.

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, Leifke E.

Lancet. 2012 Apr 14;379(9824):1403-11. doi: 10.1016/S0140-6736(11)61879-5. Epub 2012 Feb 27.

PMID:
22374408
[PubMed - indexed for MEDLINE]
6.

Could FFAR1 assist insulin secretion in type 2 diabetes?

Bailey CJ.

Lancet. 2012 Apr 14;379(9824):1370-1. doi: 10.1016/S0140-6736(12)60165-2. Epub 2012 Feb 27. No abstract available.

PMID:
22374407
[PubMed - indexed for MEDLINE]
7.

The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.

Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P.

J Pharmacol Exp Ther. 2012 Feb;340(2):483-9. doi: 10.1124/jpet.111.187708. Epub 2011 Nov 21.

PMID:
22106100
[PubMed - indexed for MEDLINE]
Free Article
8.

GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.

Araki T, Hirayama M, Hiroi S, Kaku K.

Diabetes Obes Metab. 2012 Mar;14(3):271-8. doi: 10.1111/j.1463-1326.2011.01525.x. Epub 2011 Dec 22.

PMID:
22051148
[PubMed - indexed for MEDLINE]
9.

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.

Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K.

J Pharmacol Exp Ther. 2011 Oct;339(1):228-37. doi: 10.1124/jpet.111.183772. Epub 2011 Jul 13.

PMID:
21752941
[PubMed - indexed for MEDLINE]
Free Article
10.

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.

Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, Leifke E.

J Clin Pharmacol. 2012 Jul;52(7):1007-16. doi: 10.1177/0091270011409230. Epub 2011 May 24.

PMID:
21610201
[PubMed - indexed for MEDLINE]
11.

Molecule of the Month. TAK-875.

[No authors listed]

Drug News Perspect. 2010 Dec;23(10):667. doi: 10.1358/dnp.2010.23.10.1560199. No abstract available.

PMID:
21180652
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk